Last friday, our CDO talked at IT for Business meeting about the digital workspace and the use of immersive technologies in the evolution of work. It was a pleasure to share our experiences with famous companies like, Axa France, Bouygues Telecom Entreprises or Forrester Research!

Even if we are “small” compared to such companies, we are particularly involved in the use of such technologies because it’s a way to give better services to our customers. You remember, last year,  we used Microsoft Hololens and augmented reality to validate our industrial platform thanks to partners Molecular Devices and agence dad. It was a great success! Then we organized a special session about the use of augmented and virtual reality in laboratories at Monaco to share with other biotechnological and pharmaceutical companies.

Next step for us is to put more and more interactive and immersive contents in our services, to help results visualization and “biological understanding”. We have engaged, for example, a R&D program on Machine Learning and Articifical Intelligence and we are working now on the integration of AR glasses for BIOMIMESYS® support.

Of course, if you have questions about all these technologies, we will be happy to help you!

As describe in this new article of we see that many new trends will change our vision of the “Pharma” field. We notice that HCS Pharma are involved in almost four points : Use of augmented reality, development of precision medicine, 3D printing (not for drugs but in the drugs discovery process) and use of artificial intelligence to validate test results. It’s not bad for a young startup !

I believe that there is a consensus in the medical community that current regulations concerning drug production; moreover digital health devices or health apps are obsolete. Regulatory agencies are basically unprepared for the waves of digital innovation.

Source: The Top 10 Trends Shaping the Future of Pharma – The Medical Futurist

After having been eclipsed by Target-Based Screening, Phenotypic Screening is finally shining again

The Right Combination

“We take the idea of using drug combinations to treat a disease and apply it to the phenotypic screen. In our particular case, we have successfully employed this approach to multidrug-resistant bacteria and the Ebola virus,” expounds Wei Zheng, Ph.D., a group leader at the National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH).

Thinking Inside the Black Box

“Remember the ‘Rule of 3’ for phenotypic screens,” urges Dr. Hett. This rule refers to the right cells, the right stimulus, and the right readout. The better the disease is understood, Dr. Hett adds, the better the model system that can be constructed.

Source :

Biotechnologies are growing in Brittany ! C.RIS Pharma, specialized in in vitro and in vivo preclinical development of new active molecules, just move to their new building on “Atalante Saint-Malo” area. More than 1 000 m² are added to the entreprise with 75% of laboratories. We wish them a successful installation!

News from this link: